Ajay K. Gopal, MD

Ajay K. Gopal, MD

Professor, Department of Medicine, Division of Oncology
Director, Hematologic Malignancies Medical Oncology

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Ave E, G3-200
Seattle, WA 98109-1023

Admin Contact

Gabriel Lungstrom

Specialty / Expertise

  • Hodgkin's lymphoma
  • Chronic lymphocytic leukemia
  • Diffuse large B-cell lymphoma
  • Follicular lymphoma
  • Low-grade lymphoma
  • MALT
  • Mantle cell lymphoma
  • Marginal zone lymphoma

Research Interests

Developing novel targeted therapies for lymphomas with particular emphasis on radioimmunotherapy-based transplant conditioning regimens, low toxicity Proapoptotic agents for indolent lymphomas, and safe curative regimens for older adults with lymphoma.

Current Research Projects

Ibrutinib Long Term Extension                                                    
Sponsor: Janssen Research & Development
Title: A Phase 3b, Multicenter, Open-Label, PCI-32765 (Ibrutinib) Long-term Extension Study.

Sponsor: Millennium Pharmaceuticals, Inc.
Title: A Pilot Window Study of Ixazomib in Untreated B-NHL.

Sponsor: NCCN
Title: Androgen Receptor Targeting in Mantle Cell Lymphoma: A Pilot Trial of Enzalutamide.

Single Agent Ibrutinib (I)
Sponsor: Janssen Research & Development
Title: A Pilot Study of Single-Agent Ibrutinib (I) in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma.

Therapy with Monoclonal Antibodies
Sponsor: NIH/NCI
Title: Therapy of Lymphoma/Leukemia with Monoclonal Antibodies.

Sponsor: Pfizer
Title: A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin?s Lymphoma (NHL)

Funding Source: Cephalon Inc.
A Phase I trial of Bendamustine/Treanda (T), Rituximab (R), Etoposide (E), and Carboplatin (C) for patients with relapsed or refractory lymphoid malignancies and select untreated lymphomas.

90Y- Ibritumomab/Fludarabine
Sponsor: Spectrum Pharmaceuticals
Title: A phase II trial of high-dose 90Y-Ibritumomab tiuxetan (anti-CD20) followed by fludarabine and low-dose total body irradiation and HLA-matched allogeneic hematopoietic transplantation for patients with relapsed or refractory aggressive B-cell lymphoma.

Brentuximab Vedotin
Sponsor: Seattle Genetics
Title: A Pilot Study of Weekly Brentuximab Vedotin in Patients with CD30+Malignancies Refractory to Every ? 3 Week Brentuximab Vedotin.

Sponsor: Seattle Genetics
A Phase II Study to assess the efficacy and safety of CAL-101 in patients with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents.
Title: A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients with Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)

Sponsor: Gilead Sciences, Inc.
Title: A phase II study to Assess the Efficacy and Safety of CAL-101-11 in Patients with Relapsed or Refractory Hodgkin Lymphoma (Closed to Accrual).

Sponsor: Gilead Sciences, Inc.
Title: A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects with Indolent B-Cell Non-Hodgkin Lymphomas Refractory to Rituximab and Alkylating Agents

Sponsor: Cephalon, Inc./Teva Pharmaceuticals
Title: A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)

Sponsor: Millennium Pharmaceuticals, Inc.
Title: A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma.

Sponsor: Janssen Research & Development
Title: A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma.

Anti-LAG-3 (BMS-986016)
Sponsor: Bristol-Myers Squibb Company
Title: A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas.


Dr. Gopal received his BS from Duke University, Durham, NC, and his MD from Emory School of Medicine, Atlanta, GA. He completed his Internal Medicine Residency at Duke University Medical Center, Durham, NC, where he was selected as Assistant Chief Resident. He then completed his Medical Oncology Fellowship at the University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA in 1997.


Cowan AJ, Stevenson PA, Cassaday RD, Graf SA, Fromm JR, Wu D, Holmberg LA, Till BG, Chauncey TR, Smith SD, Philip M, Orozco JJ, Shustov AR, Green D, Libby EN 3rd, Bensinger WI, Shadman M, Maloney DG, Press OW, Gopal AK. Pretransplant Minimal Residual Disease Predicts Survival in Mantle Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation in Complete Remission. (2015 Blood Marrow Transplant)

Cowan AJ, Stevenson P, Gooley TA, Frayo SL, Oliveira GR, Smith SD, Green DJ, Roden JE, Pagel JM, Wood BL, Press OW, Gopal AK. Results of a Phase I-II Study of Fenretinide and Rituximab for Patients with B-Cell Lymphomas. Blood. Dec 2015; 126(23): 2728.

Chen R, Gopal AK, Smith SE, Ansell S, Rosenblatt JD, Savage JD, Connors JM, Engert A, Larsen EK, Huebner D, Fong A, Younes A. Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood. Dec 2015; 126(23): 2736.

Martin P, Armas A, Gopal AK, Gyan E, Wagner-Johnston ND, Walewski J, Abella S, Ye W, Philip B, Sorenson B, Vos SD. Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL). Blood. Dec 2015; 126(23):1543.

Gopal AK, Kahl BS, Flowers C, Martin P, Link BK, Ansell S, Ye W, Koh B, Abella S, Barr PM, Salles GA, Friedberg JW. Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy. Blood. Dec 2015; 126(23):2744.

Wirk B, Storer BE, Maloney DG, Gopal AK, Cassaday RD, Salit R, O'Donnell PV, Sandmaier BM, Flowers ME. Analysis of Pre-Transplant Therapy with Brentuximab Vedotin for Relapsed/Refractory Hodgkin Lymphoma on Outcomes of Reduced Intensity Conditioned Allogeneic Hematopoietic Cell Transplantation. Blood. Dec 2015, 126 (26): 4406.

O'Brien S, Davies AJ, Flinn IW, Gopal AK, Kipps TJ, Salles GA, Newcomb T, Waldapfel CC, Zhang Z, Stilgenbauer S. Idelalisib Treatment Is Associated with Improved Cytopenias in Patients with Relapsed/Refractory iNHL and CLL. Blood. Dec 2015; 126(23):1747.

Gauthier J, Holmberg L, Wu D, Bensinger WI, Gopal AK, Press OW, Maloney DG, Green DJ, Till BG, Byelykh D, Shustov AR. Bone Marrow Involvement Detected By Multi-Parameter Flow Cytometry Predicts Poor Outcome after Autologous Stem Cell Transplantation for Peripheral T-Cell Lymphoma. Blood. Dec 2015; 126(23):1972.

Gopal AK, Davies AJ, Flinn IW, Ghia P, Goy A, Salles GA, Abella S, Philip B, Sorenson B, Wagner-Johnston ND. Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Small Lymphocytic Lymphoma (SLL). Blood. Dec 2015; 126(23):2743.

Rufener GA, Olsen P, Lee SY, Jensen MC, Gopal AK, Pender B, Green DJ, Maloney DG, Riddell SR, Press OW, Till BG. Preservation of CD20-Specific Chimeric Antigen Receptor T-Cell Function in the Presence of Residual Rituximab. Blood. Dec 2015; 126(23):4428.

Vandermeer J, Winter AM, Gopal AK, Cassaday RD, Hill BT, Shustov AR, Cowan AJ, Maloney DG, Shadman M, Till BG, Soma S, Press OW, Smith SD. Poor Outcomes among Patients Failing Dose-Adjusted EPOCH in Aggressive Lymphoma: A Collaborative, Retrospective Study. Blood. Dec 2015; 126 (23):1518.

Martin PS, Jenkins IC, Gooley TA, Green DJ, Pagel JM, Lundberg SJ, Hedine LM, Rajendran JG, Shields AT, Fisher DR, Maloney DG, Appelbaum FR, Cassaday RD, Press OW, and Gopal AK. A Phase II Trial of Radioimmunotherapy-Based Autologous Transplantation with I-131 Tositumomab, Cyclophosphamide and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood. Dec 2015; 126 (23):118.

Green DJ, Jones JC, Lin Y, Frayo SL, Kenoyer AL, O'Steen S, Peters A, Frost SHL, Orozco JJ, Gopal AK, Hylarides MD, Fisher DR, Sandmaier BM, Till BG, Balkin ER, Hamlin DK, Wilbur DS, Orcutt KD, Wittrup KD, Press OW. A Novel Bispecific CD38 Antibody Eradicates Multiple Myeloma in a Mouse Model Following Yttrium-90-DOTA Capture. Blood. Dec 2015; 126 (23):118.

Salles G, Schuster SJ, de Vos S, W-J ND, Viardot A, Blum KA, Flowers CR, Jurczak WJ, Flinn IW, Kahl BS, Martin P, Kim Y, Shreay S, Will M, Sorensen B, Breuleux M, Zinzani PL, Gopal AK. Efficacy and Safety of Idelalisib in Patients with Relapsed, Rituximab and Alkylating Agent ? Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase 2 Study. Haematologica. 2016 151738.

ASH 2016 Oral Abstract Presentation: Ibrutinib as Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study.

Cassaday RD, Fromm J, Cowan AJ, Libby III EN, Philip M, Behnia S, Nartea M, Press O, Gopal AK. Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial.

Last updated: August 2017